GLAXO.BO GL

GLAXO.BO GlaxoSmithKline Pharmaceuticals Limited

Healthcare · Drug Manufacturers - General

2 · Schwach Momentum 6.7 · Neutral Beobachten

2649.00

-0.77%

Über das Unternehmen

GlaxoSmithKline Pharmaceuticals Limited manufactures, distributes, and trades in pharmaceuticals in India and internationally. The company offers vaccines, such as Infanrix Hexa for vaccination of infants against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, and disease caused by Haemophilus influenzae type B; Synflorix for active immunization of infants against pneumococcal diseases and acute otitis media; Havrix for active immunization against disease caused by Hepatitis A virus; Menveo to prevent invasive meningococcal disease; Boostrix for immunization against diphtheria, tetanus and pertussis; Fluarix Tetra for the prevention of influenza disease; Varilrix for active immunization against varicella; and Shingrix for prevention of herpes zoster and post-herpetic neuralgia. It also provides specialty medicines, such as NUCALA for severe eosinophilic asthma, eosinophilic granulomatosis with polyangiitis, and hypereosinophilic syndrome; and Trelegy Ellipta for treating chronic obstructive pulmonary disease. In addition, the company offers general medicines, including AUGMENTIN and CEFTUM, an oral antibiotic to treat bacterial infections; CobadexCZS to treat mineral and vitamins deficiency states in adult patients; Flutivate, a skin cream for adults, children and infants; Tenovate to treat inflammatory and pruritic manifestations of steroid responsive dermatosis; CALPOL to treat mild to moderate pain; ELTROXIN for hypothyroidism; CCM to treat calcium and vitamin D deficiency; NEOSPORIN for treatment of specific bacterial skin infections; BETNOVATE for skin conditions; T-BACT for bacterial skin infections; and PHYSIOGEL for dry skin associated with redness and itch. The company was formerly known as SmithKline Beecham Pharmaceuticals India Ltd. and changed its name to GlaxoSmithKline Pharmaceuticals Limited in 2001. GlaxoSmithKline Pharmaceuticals Limited was incorporated in 1924 and is based in Mumbai, India.

2.15% erwartet
84.22%
57.00
448.8B
39.14
67.68
2524.35

52-Wochen-Spanne

2649
Tief 2088 Hoch 3121
Rendite Wachstum Momentum Sicherheit Wert Gesundheit

Dividenden-Tiefenanalyse

GlaxoSmithKline Pharmaceuticals Limited (GLAXO.BO), a Drug Manufacturers - General company in the Healthcare sector, currently offers a dividend yield of 2.15%. Its dividend safety status is rated as "watch." The company has a momentum score of 6.7 on a 0-10 scale, indicating a positive recent price trend. However, specific value metrics to assess whether the stock is cheap or rich, and its current yield compared to its historical 5-year range, are not provided in the data.

Dividendenhistorie

Specific historical data regarding GlaxoSmithKline Pharmaceuticals Limited's dividend growth and consistency is not provided. The dividend history object is empty, and there is no information available on a dividend streak in years. Likewise, the 3-year and 5-year compound annual growth rates (CAGRs) for the dividend are not available in the provided data. The company's current annual dividend payment is 57.0 INR. Without this historical context, assessing the long-term trend or consistency of its dividend payments is not possible from the given information.

Dividendensicherheit

GlaxoSmithKline Pharmaceuticals Limited's dividend safety is rated as "watch." The company's payout ratio stands at 84.22% of its earnings per share, indicating that a substantial portion of earnings is allocated to dividends.

Quantic · Kostenlos

Lies den Rest zur Dividendensicherheit

Dazu die wichtigsten Risiken und worauf als Nächstes zu achten ist. Kostenlos, ohne Karte.

KI-generiert aus den Dividendendaten von Quantic · Aktualisiert am 16 Nov 2026 · Nur zur Information – keine Finanzberatung.

Auf Englisch angezeigt — eine Übersetzung folgt in Kürze.

Kursverlauf

2516 2516 2516 2026 2026-10 · 2516
Kurs

Dividendenprofil

Frequenz
—
Wachstum (TTM)
—
CAGR 3J
—
—
—

Verschuldung & Hebel

2.1%
1.77
1.43
Schulden vs Barmittel
Schulden Barmittel
Gesamtverschuldung
357.1M INR
Liquide Mittel gesamt
20.6B INR
11.9B INR

Zuletzt gemeldete Bilanzkennzahlen.

Nur zur Information – keine Finanzberatung.

Quantic · Kostenlos

Verfolge GLAXO.BO und dein ganzes Portfolio

Echte Rendite, Dividendensicherheit, Nettoeinkommen nach Steuern und dein Weg zur Freiheit — kostenlos, ohne Broker-Verbindung.

€0

Brauchst du mehr? Pro bringt mehr Portfolios, Optionseinkommen-Tracking und mehr KI. Pro ansehen →